8-K filing — Lifeward Ltd. (LFWD)
Filed: 2026-08-31 AccNo: 0001178913-26-004360 Size: 206 KB Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Stocks · News reference
Lifeward Launches Six-Mointh Pilot Program With Ottobock Care To Enable Greater Patient Access To Its ReWalk 7 Personal Exoskeleton
The agreement brings together Lifeward’s advanced personal exoskeleton technology and Ottobock Care’s established clinical expertise and regional patient care infrastructure. Through the pilot, the companies intend to
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lifeward Appoints Josh Hexter As Interim CEO, Succeeding Mark Grant, Effective September 1; Names Rami Aviram CFO Effective November 1
Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a diversified biomedical innovation company with a portfolio of commercialized neurorehabilitation products and a biomedical pipeline, today
Lifeward Q2 Adj. EPS $(1.46) Misses $(1.34) Estimate, Sales $6.623M Beat $6.530M Estimate
Lifeward (NASDAQ:LFWD) reported quarterly losses of $(1.46) per share which missed the analyst consensus estimate of $(1.34) by 8.96 percent. This is a 61.07 percent increase over losses of $(3.75) per share from the